Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.
Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codexis call to discuss first-quarter 2020 financial results and recent business progress.